ACT Stock Chart & Stats
CHF156.30
--
Market closed
CHF156.30
--
Day’s Range― - ―
52-Week RangeCHF147.32 - CHF156.39
Previous CloseN/A
VolumeN/A
Average Volume (3M)1.00
Market Cap
CHF1.54B
Enterprise ValueCHF1.78B
Total Cash (Recent Filing)CHF65.69M
Total Debt (Recent Filing)CHF90.22M
Price to Earnings (P/E)23.9
Beta0.06
Next Earnings
Oct 29, 2026EPS Estimate
1.33Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)6.70
Shares Outstanding10,176,335
10 Day Avg. Volume0
30 Day Avg. Volume1
Financial Highlights & Ratios
PEG Ratio1.35
Price to Book (P/B)6.11
Price to Sales (P/S)2.79
P/FCF Ratio39.94
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
CHF198.98Price Target Upside27.30% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)6.09
Revenue Forecast (FY)CHF567.36M
Bulls Say, Bears Say
Bulls Say
Specialty Chemicals Growth And MarginsThe specialty portfolio is becoming a larger share of sales while delivering strong margins, supported by favorable mix, higher volumes and high utilization. This mix shift can improve earnings quality and provide resilience beyond cyclical basic chemicals.
Reaffirmed Earnings OutlookMaintaining guidance after first-half sales and EBITDA growth indicates confidence in underlying demand and execution. Expected growth provides a durable earnings framework, even though quarterly results may fluctuate because of timing and project costs.
Capacity Expansion And Strategic GrowthNew capacity expands AlzChem’s ability to serve specialty applications and supports long-term volume growth. German commissioning offers nearer-term potential, while the U.S. project could broaden geographic reach and add meaningful future revenue.
Bears Say
Volatile Free Cash Flow And Higher DebtThe gap between operating cash flow and free cash flow indicates substantial investment or working-capital demands. Combined with higher debt, this can reduce financial flexibility and increase sensitivity to weaker margins or delayed project returns.
Agriculture And Fertilizer Market WeaknessWeak farm economics and structural cost disadvantages can keep fertilizer demand and profitability under pressure beyond one quarter. This limits the contribution of a cyclical business area while the group relies more heavily on specialty chemicals.
Refurbishment, Ramp-up And Input-cost PressureMaintenance outages and new-facility ramp-up costs will weigh on near-term profitability and may delay the benefits of added capacity. If energy or raw-material increases cannot be fully passed through, margins could remain pressured after the outage.
AlzChem Group AG News
ACT FAQ
What was AlzChem Group AG’s price range in the past 12 months?
AlzChem Group AG lowest stock price was CHF147.32 and its highest was CHF156.39 in the past 12 months.
What is AlzChem Group AG’s market cap?
AlzChem Group AG’s market cap is CHF1.54B.
When is AlzChem Group AG’s upcoming earnings report date?
AlzChem Group AG’s upcoming earnings report date is Oct 29, 2026 which is in 15 days.
How were AlzChem Group AG’s earnings last quarter?
AlzChem Group AG released its earnings results on Jul 30, 2026. The company reported CHF1.548 earnings per share for the quarter.
Is AlzChem Group AG overvalued?
According to Wall Street analysts AlzChem Group AG’s price is currently Undervalued.
Does AlzChem Group AG pay dividends?
AlzChem Group AG does not currently pay dividends.
What is AlzChem Group AG’s EPS estimate?
AlzChem Group AG’s EPS estimate is 1.33.
How many shares outstanding does AlzChem Group AG have?
AlzChem Group AG has 10,176,335 shares outstanding.
What happened to AlzChem Group AG’s price movement after its last earnings report?
AlzChem Group AG reported an EPS of CHF1.548 in its last earnings report. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of AlzChem Group AG?
Currently, no hedge funds are holding shares in CH:ACT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
AlzChem Group AG Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
CHF198.98 (27.30% Upside)
CHF198.98 (27.30% Upside)
Insider Transactions
Bought Shares
Worth CHF1.7M over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Negative
20 days / 200 days
Momentum
4.85%
12-Months-Change
Fundamentals
Return on Equity
26.12%
Trailing 12-Months
Asset Growth
21.91%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
AlzChem Group AG
Alzchem Group AG engages in the provision of development, production, and marketing of chemical products. It operates through the following segments: Specialty Chemicals, Basics & Intermediates, and Other & Holding. The Specialty Chemicals segment focuses on the production and distribution of growth products that contain specialty chemicals such as CreAMINO, Creapure, BioSelect, Silzot, DYHARD, and Dormex. The Basics & Intermediates segment covers the production of basic and intermediate products. The Other & Holding segment comprises services to the chemical parks in Trostberg and Hart. The company was founded on October 10, 1984 is headquartered in Trostberg, Germany.
ACT Stock 12 Month Forecast
Average Price Target
CHF198.98
▲(27.30% Upside)